LOXL2 and breast carcinoma: Evidence has shown it remains bioactive in the extracellularmatrix (ECM) for extended periods of time, promotes extracellularmatrix remodeling in breast cancer through lysyl oxidase-like 2 (LOXL2)upregulation, and recruits neutrophils to cancer cells for releaseof additional OSM.−, In vivo, OSM has been shown to increasecirculating tumor cell (CTC) counts, as well as breast cancer metastasisto bone and lung.,